{"id":"lafutidine","rwe":[{"pmid":"40603444","year":"2025","title":"Addition of bedtime lafutidine inhibits nocturnal acid-breakthrough and improves sleep quality in gastroesophageal reflux disease patients on esomeprazole: a randomized controlled trial.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"39390909","year":"2024","title":"Assessing lafutidine's potential to protect lung cancer patients from chemotherapy-induced neuropathy.","finding":"","journal":"Annals of palliative medicine","studyType":"Clinical Study"},{"pmid":"37731302","year":"2023","title":"A randomized trial to evaluate the preventive effect of lafutidine on chemotherapy-induced peripheral neuropathy in patients treated with carboplatin and paclitaxel for lung cancer.","finding":"","journal":"Annals of palliative medicine","studyType":"Clinical Study"},{"pmid":"37725377","year":"2023","title":"Ranitidine Use and Incident Cancer in a Multinational Cohort.","finding":"","journal":"JAMA network open","studyType":"Clinical Study"},{"pmid":"37023725","year":"2023","title":"Lafutidine Ameliorates Indomethacin-Induced Small Intestinal Damage in Rats by Modifying the Intestinal Mucosal Barrier, Inflammation, and Microbiota.","finding":"","journal":"Pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"lafutidine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A02BA08","category":"atc"},{"label":"Active","category":"status"},{"label":"Gastro-esophageal reflux disease with esophagitis","category":"indication"},{"label":"Anti-Ulcer Agents","category":"pharmacology"},{"label":"Gastrointestinal Agents","category":"pharmacology"},{"label":"Histamine Agents","category":"pharmacology"},{"label":"Histamine Antagonists","category":"pharmacology"},{"label":"Histamine H2 Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"phase_3","safety":{"safetySignals":[{"llr":99.354,"date":"","count":54,"signal":"Platelet count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 54 times (LLR=99)"},{"llr":66.495,"date":"","count":34,"signal":"Interstitial lung disease","source":"DrugCentral FAERS","actionTaken":"Reported 34 times (LLR=66)"},{"llr":44.057,"date":"","count":32,"signal":"White blood cell count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 32 times (LLR=44)"},{"llr":37.956,"date":"","count":22,"signal":"Neutrophil count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 22 times (LLR=38)"},{"llr":33.332,"date":"","count":29,"signal":"Febrile neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 29 times (LLR=33)"},{"llr":29.49,"date":"","count":17,"signal":"Hepatic function abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 17 times (LLR=29)"}],"commonSideEffects":[{"effect":"Platelet count decreased","drugRate":"LLR 99","severity":"common"},{"effect":"Interstitial lung disease","drugRate":"LLR 66","severity":"common"},{"effect":"White blood cell count decreased","drugRate":"LLR 44","severity":"common"},{"effect":"Neutrophil count decreased","drugRate":"LLR 38","severity":"common"},{"effect":"Febrile neutropenia","drugRate":"LLR 33","severity":"common"},{"effect":"Hepatic function abnormal","drugRate":"LLR 29","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"protecadin","offLabel":[],"synonyms":["FRG 8813","FRG-8813","lafutidine","laflutidine","protecadin"],"timeline":[],"approvals":[],"brandName":"Protecadin","ecosystem":[{"indication":"Gastro-esophageal reflux disease with esophagitis","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"lafutidine","explanation":"Imagine your stomach lining has special receptors that tell it to make more acid when you eat. Protecadin blocks these receptors, so your stomach doesn't make as much acid, which helps to heal and protect the esophagus from damage.","oneSentence":"Protecadin works by blocking histamine H2 receptors to reduce stomach acid production.","technicalDetail":"Lafutidine acts as a competitive antagonist at the histamine H2 receptor, inhibiting gastric acid secretion by reducing the activity of parietal cells in the stomach."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1537","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LAFUTIDINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LAFUTIDINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:13:59.176417","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:42:24.296181+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"cimetidine","drugSlug":"cimetidine","fdaApproval":"1977-08-16","genericCount":19,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ranitidine","drugSlug":"ranitidine","fdaApproval":"1977-08-29","genericCount":44,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"famotidine","drugSlug":"famotidine","fdaApproval":"1986-10-15","genericCount":54,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nizatidine","drugSlug":"nizatidine","fdaApproval":"1988-04-12","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"lafutidine","indications":{"approved":[{"name":"Gastro-esophageal reflux disease with esophagitis","source":"DrugCentral","snomedId":266433003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"cimetidine","brandName":"cimetidine","genericName":"cimetidine","approvalYear":"1977","relationship":"same-class"},{"drugId":"ranitidine","brandName":"ranitidine","genericName":"ranitidine","approvalYear":"1977","relationship":"same-class"},{"drugId":"famotidine","brandName":"famotidine","genericName":"famotidine","approvalYear":"1986","relationship":"same-class"},{"drugId":"nizatidine","brandName":"nizatidine","genericName":"nizatidine","approvalYear":"1988","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01499368","phase":"PHASE3","title":"A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2011-11","conditions":["Erosive Esophagitis"],"enrollment":495,"completionDate":"2012-11"},{"nctId":"NCT02759224","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics of Lafutidine and Irsogladine Maleate Tablet","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-04-15","conditions":["Gastric Ulcer"],"enrollment":34,"completionDate":"2016-12-29"},{"nctId":"NCT02581696","phase":"PHASE1","title":"The Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2015-08","conditions":["Peptic Ulcer"],"enrollment":24,"completionDate":"2015-11"},{"nctId":"NCT02703896","phase":"PHASE4","title":"Prophylaxis for Aspiration of Gastric Contents.","status":"COMPLETED","sponsor":"King Saud University","startDate":"2012-01","conditions":["Pulmonary Aspiration of Gastric Contents"],"enrollment":1920,"completionDate":"2015-12"},{"nctId":"NCT02658864","phase":"PHASE1","title":"Pharmacokinetic Properties and Effect of Food on Pharmacokinetic Properties of the Oral Lafutidine Tablets","status":"COMPLETED","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2005-04","conditions":["Chronic Gastritis"],"enrollment":12,"completionDate":"2005-06"},{"nctId":"NCT02555852","phase":"","title":"Proton Pump Inhibitors and Risk of Community-acquired Pneumonia","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2011-09","conditions":["Gastroesophageal Reflux Disease (GERD)","Community-acquired Pneumonia"],"enrollment":4238504,"completionDate":"2012-02"},{"nctId":"NCT00229424","phase":"PHASE3","title":"Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2005-04","conditions":["Gastroesophageal Reflux"],"enrollment":325,"completionDate":"2007-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"49S4O7ADLC","CHEBI":"CHEBI:31759","INN_ID":"7173","UMLSCUI":"C0172827","ChEMBL_ID":"CHEMBL1742461","KEGG_DRUG":"D01131","DRUGBANK_ID":"DB12770","PUBCHEM_CID":"5282136","MESH_SUPPLEMENTAL_RECORD_UI":"C076948"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":109,"therapeuticAreas":["Gastroenterology"],"atcClassification":{"source":"DrugCentral","atcCode":"A02BA08","allCodes":["A02BA08"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Jul 2","pmid":"40603444","title":"Addition of bedtime lafutidine inhibits nocturnal acid-breakthrough and improves sleep quality in gastroesophageal reflux disease patients on esomeprazole: a randomized controlled trial.","journal":"Scientific reports"},{"date":"2024 Nov","pmid":"39390909","title":"Assessing lafutidine's potential to protect lung cancer patients from chemotherapy-induced neuropathy.","journal":"Annals of palliative medicine"},{"date":"2023 Nov","pmid":"37731302","title":"A randomized trial to evaluate the preventive effect of lafutidine on chemotherapy-induced peripheral neuropathy in patients treated with carboplatin and paclitaxel for lung cancer.","journal":"Annals of palliative medicine"},{"date":"2023 Sep 5","pmid":"37725377","title":"Ranitidine Use and Incident Cancer in a Multinational Cohort.","journal":"JAMA network open"},{"date":"2023","pmid":"37023725","title":"Lafutidine Ameliorates Indomethacin-Induced Small Intestinal Damage in Rats by Modifying the Intestinal Mucosal Barrier, Inflammation, and Microbiota.","journal":"Pharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Protecadin is a small molecule that acts as a histamine H2 receptor antagonist. It is classified as an antagonist and has been identified as a histamine H2 receptor antagonist.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:42:24.296181+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}